Biopharma company Ipsen invests €52m in Blanchardstown site upgrade

  • 📰 IrishTimesBiz
  • ⏱ Reading Time:
  • 32 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 16%
  • Publisher: 77%

대한민국 뉴스 뉴스

대한민국 최근 뉴스,대한민국 헤드 라인

Paris-headquartered multinational has increased production at the west Dublin manufacturing facility by 10% this year via IrishTimesBiz

Ipsen plans to invest a further €15 million in its Blanchardstown site between 2023 and 2026, it said. The company has expanded its workforce at the facility by 20 per cent since 2019 and is focused on driving continued research and innovation through its R&D division, having grown its team of chemists and analysts by 10 per cent over the past two years.

“It’s great to see a biopharmaceutical company which has been here for over 30 years continuing to invest and grow in Ireland, particularly when the goal is to help more patients achieve a better quality of life through its medicines,” said Mr Varadkar, as he welcomed the site launch and investment announcement.

“We hope to continue building Ipsen Ireland as an important pharmaceutical manufacturing and development site within Europe. Now we welcome the continued efforts of the Irish Government to invest in the innovative medicines that will enable Ipsen Ireland to transform even more patients’ lives.”

이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오:

 /  🏆 6. in KR
 

귀하의 의견에 감사드립니다. 귀하의 의견은 검토 후 게시됩니다.

대한민국 최근 뉴스, 대한민국 헤드 라인